Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Teva
UBS
Johnson and Johnson
Baxter
Chubb
Cerilliant
Queensland Health
Daiichi Sankyo

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,781,449

« Back to Dashboard

Summary for Patent: 7,781,449
Title:Trospium chloride treatment method
Abstract:A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C.sub.min) and maximum (C.sub.max) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
Inventor(s): Kidane; Argaw (Montgomery Village, MD), Flanner; Henry H. (Montgomery Village, MD), Bhatt; Padmanabh (Rockville, MD), Raoufinia; Arash (McLean, VA)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:11/889,963
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,781,449

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,781,449

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,781,448 Once daily dosage forms of trospium ➤ Sign Up
7,410,978 Once daily dosage forms of trospium ➤ Sign Up
7,759,359 Method of treating bladder dysfunction with once-a-day trospium salt formulation ➤ Sign Up
7,763,635 Once daily dosage forms of trospium ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,781,449

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 5610663 ➤ Sign Up
Japan 2007510656 ➤ Sign Up
Hong Kong 1088547 ➤ Sign Up
Denmark 2210605 ➤ Sign Up
European Patent Office 1680110 ➤ Sign Up
Germany 602004030931 ➤ Sign Up
Japan 2012144577 ➤ Sign Up
Japan 5783489 ➤ Sign Up
Portugal 2210605 ➤ Sign Up
Canada 2537103 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
UBS
Colorcon
Baxter
Daiichi Sankyo
Moodys
Harvard Business School
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot